Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute ST Segment Elevation Myocardial Infarction

Interventions

BIOLOGICAL: RPH-104 80 mg
DRUG: Placebo

Sponsor

R-Pharm Overseas, Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]